Stemson raised $15M for haircloning, with hopes it becomes a reality in 10-20 years. Users are hopeful and discuss using Minoxidil and finasteride in the meantime.
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.
Haircloning updates, with potential costs ranging from $200,000 to $350,000. Clinical trials may start in 2020, and some hope for cheaper options in Turkey or China.
Haircloning was predicted to be a baldness cure within 3-4 years in 2004, but it has not materialized. Users express frustration and skepticism about the delay.
The conversation humorously discusses the complexity of understanding and treating male pattern hair loss, mentioning treatments like Minoxidil, finasteride, RU58841, Dr. Brotzu's lotion, and Dr. Tsuji's haircloning. The original post satirically claims that only those with high intelligence can appreciate these treatments.
The conversation expresses frustration over the lack of progress in hair loss treatments, with specific mentions of Minoxidil, finasteride, and RU58841. Users discuss the slow development of new treatments and the potential of hair transplants.
The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.
Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.
A user is organizing a group buy for various compounds aimed at reversing hair loss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.
Dr. Tsuji and Riken announced a haircloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.
The conversation discusses potential hair loss treatments, including haircloning, setipiprant, and topical finasteride, questioning their availability and effectiveness as permanent cures. The user is inquiring about the release dates and efficacy of these treatments.
The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It also mentions ongoing human trials for hair multiplication/cloning at Yokohama National University, with skepticism about the timeline.
The conversation discusses promising haircloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.
The conversation discusses haircloning trials expected to start in 2020-2021 and mentions concerns about potential delays due to the Coronavirus. Treatments like Minoxidil, finasteride, and RU58841 are referenced.
Hair follicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.
Haircloning is unlikely to be available soon, with estimates ranging from 10 to 20 years away. Current treatments like Minoxidil, finasteride, and RU58841 are still the main options.
The conversation discusses haircloning progress and mentions treatments like Minoxidil, finasteride, and RU58841. Users also talk about hair transplants and their effectiveness.
L'Oreal is working on haircloning, with multiple companies using similar techniques, making haircloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of haircloning solutions.
The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It highlights an interview with Stemson Therapeutics CEO Geoff Hamilton about advancements in haircloning technology.
Yokohama University and Dr. Fukuda plan human hair multiplication trials in 2023. Users express hope for future haircloning treatments over current hair transplants.
Haircloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.
The struggles of hair loss at a young age and available treatments, such as medication (Finasteride, Minoxidil, Dutasteride, Derma Rolling) and potential options for hair systems or cloning in Japan. People discussed their own experiences with trying to cope with the emotional aspects of this condition.
HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
The conversation discusses the lack of significant advancements in hair loss treatments since the introduction of finasteride 22 years ago, with many expressing frustration over the failure of new projects and skepticism about future developments. Some users mention hair transplants and other potential alternatives like Alfatradiol and Fluridil, but acknowledge finasteride's dominance in the market due to its effectiveness and affordability.
A new hair loss treatment theory beyond minoxidil and finasteride is proposed, causing mixed reactions in the community, with some members eager to explore and support it, while others call for more research and evidence.
The conversation advises against waiting for future hair loss treatments and suggests using proven treatments like Finasteride and Minoxidil. Some users regret not starting treatment earlier, while others discuss the effectiveness and safety of current treatments and the potential of microneedling.
The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.